Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clazosentan - Idorsia Pharmaceuticals

Drug Profile

Clazosentan - Idorsia Pharmaceuticals

Alternative Names: ACT-108475; AXV 034; AXV 034343; Clazosentan sodium; PIVLAZ; RO-61-1790; VML-588

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Idorsia Pharmaceuticals
  • Class Antispasmodics; Dioxanes; Neuroprotectants; Phenyl ethers; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral vasospasm
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebral vasospasm

Most Recent Events

  • 20 Jul 2023 Sosei Heptares acquires territory rights for Idorsia Pharmaceuticals' clazosentan in Japan and APAC (ex China)
  • 07 Feb 2023 Idorsia Pharmaceuticals intends to launch Clazosentan in South Korea for the treatment of Cerebral Vasospam
  • 06 Feb 2023 Idorsia announces that the phase III REACT trial in Cerebral vasospasm did not meet the primary endpoint
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top